Start Date
October 10, 2021
Primary Completion Date
April 8, 2026
Study Completion Date
April 7, 2029
CC-220
CC-220
Polatuzumab vedotin
Polatuzumab vedotin
Rituximab
Rituximab
Tafasitamab
Tafasitamab
Gemcitabine
Gemcitabine
Cisplatin
Cisplatin
Dexamethasone
Dexamethasone
Bendamustine
Bendamustine
Lenalidomide
Lenalidomide
Cliniques Universitaires Saint-Luc, Brussels
Seoul National University Hospital, Seoul
Universitätsklinikum St. Pölten, Sankt Pölten
Hôpital de Jolimont, La Louvière
Medizinische Universität Graz, Graz
H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare
Hospital Universitario Germans Trias i Pujol, Badalona
National Taiwan University Hospital, Taipei, Zhongzheng Dist.
Taipei Veterans General Hospital, Beitou District, Taipei City
Hôpital François Mitterand, Dijon
Hospital Universitario 12 de Octubre, Madrid
EDOG - Institut Claudius Regaud - PPDS, Toulouse
EDOG - Institut Bergonie - PPDS, Bordeaux
Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca
Taichung Veterans General Hospital, Taichung
Hospital Universitario Virgen del Rocio - PPDS, Seville
University of Michigan Comprehensive Cancer Center, Ann Arbor
Avera Cancer Institute, Sioux Falls
Centre Hospitalier Lyon Sud, Lyon
Gustave Roussy, Villejuif
Beth Israel Deaconess Medical Center, Boston
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Beatson West of Scotland Cancer Centre, Glasgow Scotland
Royal Liverpool University Hospital, Liverpool
Nottingham University Hospitals NHS Trust, Nottingham
University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton
Lead Sponsor
Celgene
INDUSTRY